TEE
VNDA icon

Tibra Equities Europe’s Vanda Pharmaceuticals VNDA Stock Holding History

Tibra Equities Europe’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-30,700
Closed -$565K – 438
2019
Q1 		$565K Buy
+30,700
New +$700K 0.06% 253

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Tibra Equities Europe's VNDA Position: Q2 2019 in Review

Tibra Equities Europe sold out of Vanda Pharmaceuticals (VNDA) in Q2 2019, closing a stake of 30,700 shares — an estimated $565K sold.

Tibra Equities Europe first reported a position in VNDA in Q1 2019 and held it in 1 quarter. The position peaked at $565K in Q1 2019. 164 funds tracked by Wall St. Rank hold VNDA as of Q2 2019.

  • Tibra Equities Europe reported no remaining Vanda Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 30,700 Vanda Pharmaceuticals shares in Q2 2019, an estimated $565K.
  • Tibra Equities Europe first reported a position in Vanda Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Tibra Equities Europe's Vanda Pharmaceuticals position peaked at $565K in Q1 2019.
  • 164 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.